×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FULC – fulcrum therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FULC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
08:42 am
fulc
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
3/3
08:30 am
fulc
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Medium
Report
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
2/25
10:35 am
fulc
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
2/24
06:04 pm
fulc
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
Medium
Report
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
2/24
03:07 pm
fulc
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
Medium
Report
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
2/24
12:17 pm
fulc
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
07:01 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
High
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
2/24
07:00 am
fulc
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
High
Report
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Date
Time
Symbol
Company Name
Action
%Chg
2/24/2026
07:01 am
FULC
fulcrum therapeutics, inc.
IN-LINE
Report
-13.0%
fulcrum therapeutics, inc.
10/29/2025
07:00 am
FULC
fulcrum therapeutics, inc.
MISS
Report
-5.6%
fulcrum therapeutics, inc.
7/29/2025
06:48 am
FULC
fulcrum therapeutics, inc.
BEAT
Report
-0.3%
fulcrum therapeutics, inc.
5/1/2025
07:00 am
FULC
fulcrum therapeutics, inc.
BEAT
Report
89.6%
fulcrum therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/24
07:16 am
fulc
Form S-8 Fulcrum Therapeutics,
Medium
Report
Form S-8 Fulcrum Therapeutics,
2/24
07:11 am
fulc
Form 10-K Fulcrum Therapeutics, For: Dec 31
High
Report
Form 10-K Fulcrum Therapeutics, For: Dec 31
2/24
07:05 am
fulc
Form 8-K Fulcrum Therapeutics, For: Feb 24
Medium
Report
Form 8-K Fulcrum Therapeutics, For: Feb 24
2/17
04:30 pm
fulc
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
2/4
04:15 pm
fulc
Form 4/A Fulcrum Therapeutics, For: Jan 02 Filed by: Gould Robert J
Medium
Report
Form 4/A Fulcrum Therapeutics, For: Jan 02 Filed by: Gould Robert J
2/4
04:10 pm
fulc
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Oltmans Curtis Gale
Medium
Report
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Oltmans Curtis Gale
2/4
04:10 pm
fulc
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Musso Alan A
Medium
Report
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Musso Alan A
2/4
04:10 pm
fulc
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Gould Robert J
Medium
Report
Form 4 Fulcrum Therapeutics, For: Feb 02 Filed by: Gould Robert J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
25.0%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
2/14 Form SC 13G Fulcrum Therapeutics, Filed by: GLAXOSMITHKLINE PLC 21.7%
8/19 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD 21.2%
12/17 Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC) [Yahoo! Finance News] 15.4%
10/30 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 15.1%
2/26 Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) 13.2%
2/20 Fulcrum Therapeutics to Participate in Upcoming Investor Conferences 10.3%
8/26 Form 8-K Fulcrum Therapeutics, For: Aug 26 8.8%
4/29 Form DEF 14A Fulcrum Therapeutics, For: Jun 11 8.6%
4/16 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 6.6%
TOP News Decliners
8/1
Fulcrum Therapeutics to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
-12.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
8/14 Form SEC STAFF LETTER Fulcrum Therapeutics, -10.3%
3/10 Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript [The Motley Fool] -9.2%
8/15 Fulcrum Therapeutics (NASDAQ: FULC) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. -8.8%
1/21 Fulcrum Therapeutics (NASDAQ: FULC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.6%
7/17 Form 3 Fulcrum Therapeutics, For: Jul 17 Filed by: Third Rock Ventures GP IV, L.P. -6.9%
4/13 Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease -6.3%
7/18 Form 4 Fulcrum Therapeutics, For: Jul 18 Filed by: Cadavid Diego -6.3%
4/17 Fulcrum Therapeutics (NASDAQ: FULC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
3/5 Form 10-K Fulcrum Therapeutics, For: Dec 31 -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: